Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 1.4% – Should You Sell?

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) were down 1.4% during mid-day trading on Thursday . The stock traded as low as GBX 734 and last traded at GBX 750. Approximately 9,378 shares traded hands during trading, a decline of 65% from the average daily volume of 26,501 shares. The stock had previously closed at GBX 761.

Hemogenyx Pharmaceuticals Stock Performance

The company has a market capitalization of £51 million, a price-to-earnings ratio of -4.40 and a beta of 1.50. The company has a current ratio of 1.38, a quick ratio of 6.72 and a debt-to-equity ratio of 167.66. The stock has a 50-day simple moving average of GBX 732.91 and a 200-day simple moving average of GBX 810.24.

Hemogenyx Pharmaceuticals (LON:HEMO) last released its quarterly earnings results on Thursday, April 30th. The company reported GBX (170.60) earnings per share for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.